Proglumide
Proglumide is a cholecystokinin (CCK) receptor antagonist that blocks both CCK-A and CCK-B receptor subtypes, thereby reducing gastric acid secretion stimulated by gastrin and CCK, and also demonstrating analgesic-potentiating properties through its interaction with endogenous opioid pathways. It was investigated for the treatment of peptic ulcer disease and chronic pain management.
Peso molecular
334,4000 g/mol
LogP
2,40
TPSA
86,70 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)c1ccccc1
InChI
InChI=1S/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22)
Molecular Formula
C18H26N2O4
HBD / HBA
2 / 4
Enlaces Rotables
10
Átomos Pesados
24
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Proglumide is a cholecystokinin (CCK) receptor antagonist that blocks both CCK-A and CCK-B receptor subtypes, thereby reducing gastric acid secretion stimulated by gastrin and CCK, and also demonstrating analgesic-potentiating properties through its interaction with endogenous opioid pathways. It was investigated for the treatment of peptic ulcer disease and chronic pain management.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Proglumide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL316561. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 4922. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="proglumide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/proglumide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/proglumide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/proglumide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="proglumide"></drugfyi-drug>